uniQure Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Für uniQure wird ein Gewinn- und Umsatzwachstum von 31.5% bzw. 52.2% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 34.8% pro Jahr steigen soll.
Wichtige Informationen
31.5%
Wachstumsrate der Gewinne
34.75%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.3% |
| Wachstumsrate der Einnahmen | 52.2% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 06 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 20
QURE: Shifting FDA Leadership Will Reopen Path For Huntington’s Gene Therapy Approval
uniQure's updated analyst price target of $39.05 reflects a modest upward reset, supported by analysts' mixed but generally constructive views on AMT-130's regulatory path and the broader gene therapy pipeline. Analyst Commentary Recent research on uniQure shows a split view, with some analysts turning more constructive after changes at the FDA, while others stay cautious given the regulatory uncertainty and development timelines around AMT-130.Seeking Alpha • May 12
UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play
Summary UniQure is upgraded from Hold to Buy, driven by near-term UK approval prospects for AMT-130 and a robust cash runway to 2029. Despite FDA requiring a new Phase 3 trial for AMT-130 in Huntington's, a UK submission is imminent, positioning QURE for a major catalyst. QURE’s pipeline, including AMT-260 for epilepsy and AMT-191 for Fabry, offers additional upside, though AMT-162 was discontinued. With potential UK approval, $750m peak annual revenue by 2030 is projected, and QURE’s valuation could trend toward $3bn if milestones are met. It will additionally be intriguing to see if high-profile departures at the FDA, plus updated four-year data from a Phase 1/2 study, soften the FDA's stance on approval. Read the full article on Seeking AlphaAnalyseartikel • May 08
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates
Shareholders will be ecstatic, with their stake up 21% over the past week following uniQure N.V. 's ( NASDAQ:QURE...Narrativ-Update • May 03
QURE: FDA Leadership Shift Will Reshape Gene Therapy Approval Path
Analysts have lifted uniQure's price targets, with moves such as Chardan's $15 increase to $31 and Wells Fargo's $45 increase to $60. They cite an improved regulatory backdrop for AMT-130 and a reassessment of the company's risk and reward profile.Narrativ-Update • Apr 09
QURE: Shifting FDA Leadership Will Reopen Rare Disease Gene Therapy Discussions
Analysts trimmed their average uniQure price target by $6, with the shift reflecting concern around the FDA's call for a sham surgery controlled Phase 3 trial for AMT-130, even as some research argues that recent regulatory leadership changes could improve the discussion around rare disease approvals. Analyst Commentary Recent research covers a wide spectrum of views on uniQure, with opinions clustered around how the FDA's stance on AMT-130 and agency leadership changes could influence valuation, timelines, and competitive positioning.Narrativ-Update • Mar 24
QURE: Evolving FDA Leadership Will Shape Future Gene Therapy Upside
The updated analyst price target for uniQure moves higher to around $38, supported by analysts who see improved regulatory prospects for AMT-130 and the broader pipeline following recent FDA leadership changes, even as views on timelines and trial requirements remain mixed. Analyst Commentary Recent research shows a sharp split in how analysts think about uniQure, with some pointing to a more flexible regulatory backdrop as a key upside driver and others staying focused on trial risk, ethics concerns, and competitive pressure in Huntington's disease.Narrativ-Update • Mar 07
QURE: Future FDA Trial Resolution Will Drive Gene Therapy Upside
Analysts have cut their fair value estimate for uniQure from about $53.54 to $28.67 as they reassess the impact of the FDA's push for a randomized, sham-controlled Phase 3 trial for AMT-130. They are applying a higher discount rate, moderating revenue growth and profit margin assumptions, and using a much higher future P/E multiple to reflect greater uncertainty in the path to commercialization.Narrativ-Update • Feb 21
QURE: Future Huntington’s FDA Decisions Will Drive Gene Therapy Upside
Analysts have trimmed their fair value estimate for uniQure to about $53.54 from roughly $54.42. This reflects slightly higher discount rate assumptions and modest tweaks to growth and margin expectations after recent neutral Street research coverage.Narrativ-Update • Feb 07
QURE: Future FDA Path On Huntington’s Program Will Drive Gene Therapy Upside
Analysts have trimmed their fair value estimate for uniQure from about $55.27 to $54.42. This reflects updated views on discount rates, revenue growth, profit margins and future P/E following recent neutral Street research coverage.Narrativ-Update • Jan 21
QURE: Future FDA Clarity On Huntington’s Data Requirements Will Drive Gene Therapy Upside
Narrative Update Analysts have trimmed their fair value estimate for uniQure only slightly, with the implied price target moving lower by a few dollars as they factor in a higher discount rate, modestly stronger profit margin assumptions, and fresh regulatory uncertainty around AMT-130 following recent FDA feedback and price target cuts from several firms. Analyst Commentary Street research on uniQure is clustered around the FDA’s shift on AMT-130 in Huntington’s disease, and what that means for valuation, risk, and timing.Narrativ-Update • Jan 07
QURE: Future Regulatory Clarity On Huntington’s Pathway Will Drive Gene Therapy Upside
Narrative Update: uniQure Analysts have cut their price targets on uniQure, with one moving from US$56 to US$38, another from US$76 to US$53, and a third from US$65 to US$45. These changes reflect concerns about the FDA's decision not to support a BLA filing for AMT-130 in Huntington's disease based on current Phase 1/2 data and the resulting uncertainty around the program's regulatory path and timing.Narrativ-Update • Dec 17
QURE: Future Regulatory Clarity Will Drive Gene Therapy Upside Despite FDA Setback
The analyst price target for uniQure has been reduced from $56 to $38 as analysts factor in heightened regulatory uncertainty around AMT-130, a higher perceived discount rate, and more conservative revenue growth expectations, despite still-supportive long term Huntington's disease data. Analyst Commentary Analyst views on uniQure have shifted rapidly from optimism following the three year AMT 130 data to caution after the FDA withdrew support for a BLA based on the current Phase 1 2 package.Narrativ-Update • Dec 03
QURE: Future Regulatory Clarity Will Unlock Gene Therapy Upside Despite Delays
Analysts have modestly reduced their average price target for uniQure, reflecting greater regulatory uncertainty and a longer timeline to monetize AMT-130 in Huntington's disease, while still recognizing meaningful long term revenue growth potential. Analyst Commentary Recent Street research reflects a sharp swing from earlier optimism to a more balanced and risk aware stance on uniQure, with price targets reset lower but not uniformly bearish.Narrativ-Update • Nov 19
QURE: Regulatory Path Clarity Will Drive Share Recovery After Recent FDA Setback
uniQure's analyst price target has been lowered notably, with estimates now around $38 to $58 per share from previous targets as high as $76, as analysts cite increased regulatory uncertainty following the FDA's recent withdrawal of support for AMT-130's current data package in Huntington's disease. Analyst Commentary Recent street research offers a wide range of perspectives on uniQure’s outlook following regulatory setbacks and key data releases.Narrativ-Update • Nov 01
QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake
uniQure's analyst price targets have been raised substantially, with increases ranging from $24 to as high as $80 per share. Analysts cite strong three-year Huntington's disease trial data and growing confidence in the approval and impact of AMT-130.Narrativ-Update • Oct 18
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
Analysts have raised their price target for uniQure from approximately $66 to $75 per share. They cite strong three-year AMT-130 data in Huntington's disease, as well as increased confidence in the therapy's clinical profile and approval pathway.Narrativ-Update • Oct 04
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
uniQure's analyst price targets have surged, with fair value estimates nearly doubling from around $35 to $66 per share. Analysts point to robust, statistically significant AMT-130 data in Huntington's disease, which supports higher revenue growth expectations and dramatically improved profitability assumptions.Narrativ-Update • Sep 18
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
uniQure’s consensus price target was revised down from $36.96 to $34.94 as analysts balance optimism around AMT-130’s differentiated approach and near-term data catalysts with procedural concerns and selling pressure, resulting in a modest fair value decrease. Analyst Commentary Bullish analysts view the recent share selloff driven by absence of AMT-130 Phase 1/2 three-year data as a buying opportunity, emphasizing management’s reassurance that the data remains on schedule for September.Narrativ-Update • Aug 27
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
The consensus Analyst Price Target for uniQure has risen to $36.96, reflecting increased optimism for AMT-130’s commercial potential and near-term regulatory catalysts, supported by a strong cash position and resolution of technical valuation concerns. Analyst Commentary Bullish analysts see AMT-130 as a potential dominant therapy in Huntington's disease, not susceptible to AAV-related acute liver failure concerns due to direct brain administration.Neues Narrativ • May 11
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment.Analyseartikel • May 10
Is uniQure (NASDAQ:QURE) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 19
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
Summary uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operations through H2 2027, reducing immediate financial risk. AMT-191 for Fabry Disease and AMT-162 for ALS are also advancing, diversifying uniQure's pipeline and potential market impact. FDA type B meeting to be held in Q2 of 2025 to discuss the possibility of Accelerated Approval of AMT-130 for the treatment of patients with HD. Read the full article on Seeking AlphaSeeking Alpha • Feb 20
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
Summary uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $251m in cash and $183m in securities, despite a $100m net loss in the first 9m of 2025. uniQure's strategic moves, including selling its Lexington facility and reducing cash burn, indicate a strong, focused approach towards achieving commercial success with AMT-130. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles
Summary uniQure N.V.'s AMT-130 demonstrated an 80% reduction in disease progression for high-dose patients, supported by biomarker data. Huntington's disease affects 41,000 people in the U.S., and the market is projected to grow to $3 billion by 2032, underscoring significant demand. If approved, AMT-130 faces adoption challenges due to its invasive brain surgery delivery and high cost, typical of gene therapies. uniQure's cash position and royalties from Hemgenix sales provide some financial stability, enabling continued pipeline development. Despite AMT-130's promise, commercialization challenges, cash burn, and strong competition from oral options like PTC518 warrant a cautious investment stance (“hold”). Read the full article on Seeking AlphaAnalyseartikel • Dec 07
Is There An Opportunity With uniQure N.V.'s (NASDAQ:QURE) 39% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, uniQure fair value estimate is US$12.16 Current share price of...Seeking Alpha • Oct 21
uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring
Summary uniQure N.V. leverages AAV technology to develop gene therapies for liver and CNS diseases, with one FDA-approved treatment and multiple investigational drugs in its pipeline. Despite promising technology and an FDA Orphan Drug designation for AMT-191, QURE's early-stage pipeline and ongoing restructuring add significant risk. The Company's valuation appears slightly high relative to peers, with limited upside potential, making it prudent to rate the stock as a "Hold" for now. Monitoring QURE's next quarterly report is crucial to assess the impact of its restructuring and potential progress in its pipeline. Read the full article on Seeking AlphaSeeking Alpha • Aug 06
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
Summary uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington's Disease, leading to a significant stock price increase. The company has aggressively restructured to extend its cash runway, focusing on AMT-130 development with confidence in its success. Despite risks, including potential negative trial data, its strong balance sheet and upcoming catalysts make it possible for QURE stock to reach $15 by year-end. Read the full article on Seeking AlphaAnalyseartikel • Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
uniQure N.V. ( NASDAQ:QURE ) just released its quarterly report and things are looking bullish. Overall results were...Seeking Alpha • Jul 09
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
Summary uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression. The company plans to meet with the FDA in H2 2024 to discuss the possible Accelerated Approval pathway of AMT-130 for the treatment of patients with Huntington's Disease. 36-month data from the phase 1/2 studies using AMT-130 for the treatment of patients with Huntington's Disease is expected in mid-2025. The global Huntington's Disease market is projected to reach $1.21 billion by 2032. Read the full article on Seeking AlphaAnalyseartikel • Mar 03
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
There's been a notable change in appetite for uniQure N.V. ( NASDAQ:QURE ) shares in the week since its annual report...Seeking Alpha • Feb 01
uniQure: The Valuation Got More Attractive
Summary uniQure is valued here as a pre-revenue company assessing its liquidation value, value of potential cash flows from HEMGENIX sales and estimating the worth of its future R&D efforts. In 2023, uniQure achieved some major milestones – approval for its HEMGENIX treatment in US & EU, sale of its royalty interests in it, encouraging data from Huntington’s disease trials. With the value for uniQure close to $33/share, it represents a very attractive bargain, trading at below $6 recently. Read the full article on Seeking AlphaAnalyseartikel • Jan 17
Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
uniQure N.V. ( NASDAQ:QURE ) shares have had a horrible month, losing 29% after a relatively good period beforehand...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 163 | -151 | -234 | -187 | 7 |
| 12/31/2027 | 76 | -211 | -214 | -143 | 11 |
| 12/31/2026 | 23 | -200 | -173 | -213 | 12 |
| 3/31/2026 | 18 | -209 | -173 | -172 | N/A |
| 12/31/2025 | 16 | -199 | -178 | -178 | N/A |
| 9/30/2025 | 16 | -235 | -154 | -153 | N/A |
| 6/30/2025 | 14 | -199 | -174 | -173 | N/A |
| 3/31/2025 | 20 | -218 | -167 | -166 | N/A |
| 12/31/2024 | 27 | -240 | -186 | -183 | N/A |
| 9/30/2024 | 29 | -240 | -185 | -179 | N/A |
| 6/30/2024 | 28 | -285 | -111 | -104 | N/A |
| 3/31/2024 | 19 | -297 | -135 | -128 | N/A |
| 12/31/2023 | 16 | -308 | -153 | -146 | N/A |
| 9/30/2023 | 112 | -228 | -161 | -151 | N/A |
| 6/30/2023 | 112 | -187 | -251 | -239 | N/A |
| 3/31/2023 | 110 | -157 | -214 | -198 | N/A |
| 12/31/2022 | 106 | -127 | -163 | -145 | N/A |
| 9/30/2022 | 61 | -125 | -154 | -137 | N/A |
| 6/30/2022 | 62 | -114 | -149 | -129 | N/A |
| 3/31/2022 | 525 | 324 | 286 | 304 | N/A |
| 12/31/2021 | 524 | 330 | 271 | 288 | N/A |
| 9/30/2021 | 500 | 321 | 281 | 298 | N/A |
| 6/30/2021 | 500 | 303 | 292 | 303 | N/A |
| 3/31/2021 | 38 | -139 | -154 | -143 | N/A |
| 12/31/2020 | 38 | -125 | -144 | -135 | N/A |
| 9/30/2020 | 6 | -166 | -132 | -124 | N/A |
| 6/30/2020 | 5 | -136 | -120 | -111 | N/A |
| 3/31/2020 | 6 | -124 | -114 | -105 | N/A |
| 12/31/2019 | 7 | -124 | N/A | -99 | N/A |
| 9/30/2019 | 6 | -105 | N/A | -91 | N/A |
| 6/30/2019 | 8 | -103 | N/A | -89 | N/A |
| 3/31/2019 | 9 | -92 | N/A | -81 | N/A |
| 12/31/2018 | 11 | -83 | N/A | -76 | N/A |
| 9/30/2018 | 12 | -90 | N/A | -76 | N/A |
| 6/30/2018 | 11 | -78 | N/A | -71 | N/A |
| 3/31/2018 | 13 | -78 | N/A | -74 | N/A |
| 12/31/2017 | 13 | -79 | N/A | -64 | N/A |
| 9/30/2017 | 20 | -67 | N/A | -62 | N/A |
| 6/30/2017 | 25 | -72 | N/A | -65 | N/A |
| 3/31/2017 | 24 | -71 | N/A | -68 | N/A |
| 12/31/2016 | 25 | -73 | N/A | -72 | N/A |
| 9/30/2016 | 20 | -76 | N/A | -81 | N/A |
| 6/30/2016 | 16 | -90 | N/A | -62 | N/A |
| 3/31/2016 | 14 | -90 | N/A | 5 | N/A |
| 12/31/2015 | 11 | -82 | N/A | 7 | N/A |
| 9/30/2015 | 8 | -76 | N/A | 22 | N/A |
| 6/30/2015 | 6 | -58 | N/A | 13 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: QURE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: QURE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: QURE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: QUREDie Einnahmen des Unternehmens (52.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: QUREDie Einnahmen des Unternehmens (52.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von QURE in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 23:13 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
uniQure N.V. wird von 33 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Madhu Kumar | Baird |
| Eliana Merle | Barclays |
| Vincent Chen | Bernstein |